Citigroup’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-107,635
| Closed | -$649K | – | 7950 |
|
|
2019
Q4 | $649K | Sell |
107,635
-319,801
| -75% | -$1.85M | ﹤0.01% | 4186 |
|
|
2019
Q3 | $1.54M | Buy |
427,436
+106,040
| +33% | +$409K | ﹤0.01% | 3149 |
|
|
2019
Q2 | $861K | Buy |
321,396
+293,712
| +1,061% | +$867K | ﹤0.01% | 3815 |
|
|
2019
Q1 | $82K | Sell |
27,684
-340,046
| -92% | -$835K | ﹤0.01% | 5940 |
|
|
2018
Q4 | $584K | Buy |
367,730
+148,666
| +68% | +$420K | ﹤0.01% | 3963 |
|
|
2018
Q3 | $806K | Buy |
219,064
+30,757
| +16% | +$91.7K | ﹤0.01% | 3741 |
|
|
2018
Q2 | $533K | Buy |
188,307
+23,897
| +15% | +$81.4K | ﹤0.01% | 4026 |
|
|
2018
Q1 | $610K | Sell |
164,410
-70,930
| -30% | -$232K | ﹤0.01% | 3790 |
|
|
2017
Q4 | $678K | Buy |
235,340
+141,118
| +150% | +$513K | ﹤0.01% | 3769 |
|
|
2017
Q3 | $423K | Sell |
94,222
-8,209
| -8% | -$36.4K | ﹤0.01% | 4287 |
|
|
2017
Q2 | $471K | Buy |
102,431
+21,077
| +26% | +$84.7K | ﹤0.01% | 4042 |
|
|
2017
Q1 | $342K | Sell |
81,354
-461,259
| -85% | -$1.92M | ﹤0.01% | 4193 |
|
|
2016
Q4 | $2.24M | Buy |
542,613
+500,568
| +1,191% | +$2.66M | ﹤0.01% | 2802 |
|
|
2016
Q3 | $340K | Buy |
42,045
+14,492
| +53% | +$123K | ﹤0.01% | 4248 |
|
|
2016
Q2 | $215K | Sell |
27,553
-89,278
| -76% | -$766K | ﹤0.01% | 4434 |
|
|
2016
Q1 | $902K | Buy |
116,831
+83,432
| +250% | +$611K | ﹤0.01% | 3452 |
|
|
2015
Q4 | $361K | Sell |
33,399
-47,309
| -59% | -$430K | ﹤0.01% | 4201 |
|
|
2015
Q3 | $558K | Buy |
80,708
+49,429
| +158% | +$403K | ﹤0.01% | 3643 |
|
|
2015
Q2 | $277K | Sell |
31,279
-13,190
| -30% | -$125K | ﹤0.01% | 4186 |
|
|
2015
Q1 | $439K | Sell |
44,469
-3,967
| -8% | -$49.5K | ﹤0.01% | 3870 |
|
|
2014
Q4 | $593K | Buy |
48,436
+28,903
| +148% | +$353K | ﹤0.01% | 3709 |
|
|
2014
Q3 | $195K | Sell |
19,533
-11,323
| -37% | -$105K | ﹤0.01% | 4261 |
|
|
2014
Q2 | $234K | Sell |
30,856
-6,280
| -17% | -$25.1K | ﹤0.01% | 4018 |
|
|
2014
Q1 | $122K | Sell |
37,136
-14,988
| -29% | -$52.5K | ﹤0.01% | 4803 |
|
|
2013
Q4 | $173K | Buy |
52,124
+16,718
| +47% | +$48.5K | ﹤0.01% | 4782 |
|
|
2013
Q3 | $107K | Buy |
35,406
+29,153
| +466% | +$200K | ﹤0.01% | 4666 |
|
|
2013
Q2 | $52K | Buy |
+6,253
| New | +$47.7K | ﹤0.01% | 5367 |
|
Citigroup's ACHN Position: Q1 2020 in Review
Citigroup sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 107,635 shares — an estimated $649K sold.
Citigroup first reported a position in ACHN in Q2 2013 and held it in 27 quarters. The position peaked at $2.24M in Q4 2016. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Citigroup reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Citigroup sold 107,635 Achillion Pharmaceuticals shares in Q1 2020, an estimated $649K.
- Citigroup first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
- Citigroup's Achillion Pharmaceuticals position peaked at $2.24M in Q4 2016.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Citigroup's 13F filing for Q1 2020, filed 12 May 2020.